Your Chief AI Officer · Tuesday, November 17, 2026 · Act today
Remedy Robotics raises $62M for remote endovascular stroke robot
Reported2 sourcesFor patients and employees
Remedy Robotics raised a $62 million Series B led by DCVC to advance its N1 System toward FDA approval, HIT Consultant reported. The company says the system, backed by 48 issued patents, is built to decouple specialist expertise from bedside presence. IEEE Spectrum examined whether robots can bring stroke surgery to remote hospitals.
Remedy Robotics, a San Francisco company building an AI-enabled endovascular robot, has raised a $62 million Series B led by returning investor DCVC, HIT Consultant reported on November 16, 2026. New investors include UC Investments, Skip Capital and Australian pension fund Hostplus. The company says proceeds will fund a planned pivotal neurovascular trial with the University of California network, expand prototype N1 System deployments through SVIN Mission Thrombectomy and the Australian Stroke Alliance, and accelerate autonomous software development. Remedy says it works with more than 100 hospitals worldwide and holds 48 issued patents.
The access problem is the reason boards should pay attention. IEEE Spectrum reports that only about 1 in 10 patients eligible for thrombectomy receive one, and cites 2025 data showing at least 5 million people worldwide suffer ischemic strokes each year. Patients in rural and remote areas lose hours in transfer from hospitals that cannot perform the procedure. Remedy's stated design goal is to separate specialist expertise from bedside presence, so an interventionalist at a hub could operate a robot at a spoke hospital, using machine learning to simulate anatomy from preoperative imaging and overlay 3D vessel maps onto live fluoroscopy.
The evidence is early. The N1 System is not FDA approved, and the pivotal trial is planned, not complete. IEEE Spectrum reports Remedy has remotely tested the system on a small group of patients, and no clinical outcome data is published in these sources. Cofounder David Bell made the point himself: "Smoothness and precision are not clinical outcomes." The article also notes that practical telesurgery depends on more than the robot, including communications infrastructure, hospital resources and workflows, and evidence that patients benefit. For a CISO, that network dependency means a remote procedure is only as reliable as the link carrying it, which belongs in any future risk review.
The move: ask your stroke program lead to map which spoke hospitals lack endovascular coverage and what a remote robotic model would require in imaging, staffing, network resilience and transfer agreements. That work has value now, regardless of which platform eventually clears review, because it shows where patients are waiting and what it would take to bring care closer to them without adding burden on the clinicians already stretched across the network.
Do this week. Ask your stroke program lead to map which spoke hospitals lack endovascular coverage and what a remote robotic model would require in imaging, staffing and transfer agreements.
Run this
The prompt to act on this item, for your own model.
Paste it into Claude, ChatGPT or Copilot and fill the bracketed slots with your own numbers. The output is a draft for your team to check, built only from the sources on this page. Never paste patient data. How these prompts are written.
You are a clinical operations advisor to the Chief Medical Officer and physician leaders of [your health system], a network with a hub and [the number of spoke hospitals in your network] spoke hospitals. Context: HIT Consultant reported on November 16, 2026 that Remedy Robotics raised a $62 million Series B led by DCVC to advance its N1 System toward FDA approval. The company says the system, backed by 48 issued patents, is built to decouple specialist expertise from bedside presence, and that it works with more than 100 hospitals worldwide. IEEE Spectrum reports that only about 1 in 10 patients eligible for thrombectomy receive one, and cites 2025 data showing at least 5 million people worldwide suffer ischemic strokes each year. The N1 System is not FDA approved, the pivotal trial is planned and not complete, and no clinical outcome data is published in these sources. IEEE Spectrum notes that telesurgery also depends on communications infrastructure, hospital resources, workflows and evidence that patients benefit. Task: prepare a question set for [your stroke program lead] to map which spoke hospitals lack endovascular coverage and what a remote robotic model would require in imaging, staffing, network resilience and transfer agreements. Treat this as readiness mapping, not a purchasing decision. Output: a one-page brief for the executive team with these sections: Why we are asking; Coverage gaps by spoke; Imaging; Staffing; Network resilience; Transfer agreements; What we will not decide yet. Under each section, list the specific questions the stroke program lead should answer. Where relevant, frame questions against [your current spoke to hub transfer time] and [your hub's current endovascular call coverage]. Guardrails: Use only the facts given above and the slots I fill. Cite HIT Consultant and IEEE Spectrum by name for each fact you use. Flag anything uncertain or that needs verifying, and treat all company statements as claims, not evidence. Do not request or include any patient data. Nothing here is medical advice. Label the output as a draft for the team to check.
- The claim.
- Remedy Robotics says the N1 System decouples specialist expertise from physical bedside presence.
- The evidence.
- The system is not FDA approved; no clinical outcome data is cited in the candidates.
By seat
For the Chief AI Officer. Add remote surgical robotics to the technology watch list with FDA status as the trigger for review.
For the CEO and board. Consider whether remote stroke intervention changes the case for hub and spoke network strategy.
For the Chief Medical Officer and physicians. Engage neurointerventional physicians on credentialing and oversight questions a remote model would raise.
Checked before publishing. 2 independent outlets. 2 figures matched to the source text.
Sources
- HIT Consultant, Remedy Robotics Raises $62M to Advance Remote Endovascular Stroke Robotics Toward FDA Approval
- IEEE Spectrum Robotics, Can Robots Bring Stroke Surgery to Remote Hospitals?
Drafted by Lumen from the sources above, scored by a second pass on six criteria, then checked by rule against those sources (every figure, two independent outlets or a primary source) and published only when it passes. A person can pull any item, and corrections are published here. Apolitical, always. Nothing here is medical advice. How Your Chief AI Officer is made.
Also in this brief
- OpenAI builds computer-use agents for referrals and prior authorization
- FBI warns AI hacking framework Artex is targeting health care
- Google Cloud report says health care struggles to scale AI past pilots
- Credo Health buys Affineon and relaunches as Pajama.ai for physician inbox work
- Figure CEO says humanoids already handle visitors on its campus